Company Performance Metrics
Judith Phillips: Company Secretary & Financial Controller- Philip Burke: Co-Founder
Morvus Technology Ltd., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs and technologies in the oncology field. Its clinical candidates include MTL-005, a therapy for cancers treated with conventional radiotherapy; MTL-007, a novel anti-cancer prodrug; and MTL-003, an anti-angiogenic cancer therapy.
The company's research portfolio comprises MorTar platform technology that identifies new proteins and genes that share the ability to inhibit apoptosis; HAI-X, an anti-angiogenic treatment for prostate cancer; and MorGen, a novel prodrug-activating system. The company also engages in the development of anti-cancer treatments using genetic modification techniques. In addition, it offers MorAnt, an anti-parasitic drug; and MorRid, a rodenticide. Morvus Technology Ltd. was founded in 2004 and is based in Carmarthen, the United Kingdom.
